The American Journal of Psychiatry
Journal Home Search Current Issue Past Issues Subscribe All APPI Journals Help Contact Us
 
Am J Psychiatry 119:172-173, August 1962
doi: 10.1176/appi.ajp.119.2.172
© 1962 American Psychiatric Association
Quicksearch
Advanced Search
Or Search All APPI Journals
This Article
* Full Text (PDF)
* Alert me when this article is cited
* Alert me if a correction is posted
Services
* Email this article to a Colleague
* Similar articles in this journal
* Similar articles in PubMed
* Alert me to new issues of the journal
* Add to My Articles & Searches
* Download to citation manager
* reprints & permissions
Citing Articles
* Citing Articles via Google Scholar
Google Scholar
* Articles by DENBER, H. C. B.
* Articles by RAJOTTE, P.
* Search for Related Content
PubMed
* PubMed Citation
* Articles by DENBER, H. C. B.
* Articles by RAJOTTE, P.

THIRD EVALUATION OF HALOPERIDOL

HERMAN C. B. DENBER M.D., DANIELLE FLORIO M.D., , and PAUL RAJOTTE M.D.1

1 Research Division, Manhattan State Hospital, New York, N. Y.

After three clinical trials, we have been unable to confirm the reported "superior neuroleptic" potential of Haloperidol. A genetic mechanism has been postulated to explain the differences, and this is being explored further(5).






Get information about faster international access.

Privacy Policy

Copyright © 1962 American Psychiatric Association. All rights reserved.

Home | Search | Current Issue | Past Issues | Subscribe | All APPI Journals | Help | Contact Us

American Psychiatric Publishing, Inc. American Psychiatric Association
1000 Wilson Boulevard, Suite 1825, Arlington, VA 22209-3901 * 800-368-5777 * appi at psych.org